VLP Therapeutics, Inc. (VLPT) researchers and their colleagues at the Stanford University School of Medicine posted on August 11 a preprint “Alphavirus replicon particle expressing IL-12 reprograms tumor-associated macrophages and neutrophils and induces anti-tumor immunity” on bioRxiv, a preprint server for biology.
Note: Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
- Abstract (full text PDF also available): https://www.biorxiv.org/content/10.1101/2025.08.07.666585v1
- Authors: Momoko Ishikawa, Dhanya K Nambiar, Jaya Sastri, Forrest Bowling, Keiko Ishimoto, Fumiya Tao, Koyo Takahashi, Ivan Stephanek, Hongbin Cao, Davis Leitner, Kenta Matsuda, Fred M Balk, John B Sunwoo, Quynh-Thu Le, Jonathan F Smith, Wataru Akahata* (*Corresponding author)
Related links:
- November 8, 2023 | [News Release] VLP Therapeutics group announces 3rd closing of funding to develop cancer, infectious disease vaccines; establish investigational vaccine manufacturing facility
- September 5, 2023 | [News Release] VLP Therapeutics group announces 2nd closing of funding to develop cancer, infectious disease vaccines, establish investigational vaccine manufacturing facility
- August 2, 2023 | [News Release] VLP Therapeutics group raises funding for developing cancer/infectious disease vaccines, establishing investigational vaccine manufacturing facility